RxDoctor Payments Data

John Oldemeyer, MD

Interventional Cardiology · Fort Collins, CONPI 1700882123

Payments from drug & device makers

What this record shows

Edwards Lifesciences accounts for 83.1% of it on its own, with 10 other manufacturers making up the rest.

$19,731in general payments, 2019–2025

Across 220 payments — averaging $89.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$16K
  • Abiomed$2K
  • Medtronic$627
  • Abbott$329
  • Shockwave Medical, Inc$292
  • Boston Scientific$235
  • plus $216 from 5 others
$2,666,023in research payments, 2019–2025

Across 199 payments — averaging $13,397 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$2.7M

What the payments were for

  • Travel & lodging$10,91555%
  • Food & beverage$8,81645%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,731 in reported general payments places this provider in the 70th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$271,496
Medicare patients
1,012
Services billed
1,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban312$426,984
XareltoRivaroxaban101$141,462
EntrestoSacubitril/Valsartan38$51,866
JardianceEmpagliflozin21$31,252
Repatha SureclickEvolocumab20$18,578
FarxigaDapagliflozin Propanediol13$18,102
Ezetimibe437$10,756
Metoprolol Succinate465$7,943
Atorvastatin Calcium665$7,497
Rosuvastatin Calcium466$5,977
Potassium Chloride112$2,774
ClopidogrelClopidogrel Bisulfate213$2,748
Losartan Potassium246$2,497
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$2,364
Carvedilol268$2,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$29$141,462101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Fort Collins

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →